Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Respironics, Inc.
News We're Watching: FDA Announces Meetings On Ortho Safety And Radiology; News Orgs Sue FDA For Philips Docs, ITC Delays Apple Watch Case; And More
This week, FDA announced plans for cybersecurity and meetings to discuss orthopedic device safety and radiological devices. ProPublica and the Pittsburgh Post-Gazette insist that the FDA to divulge more information about the ongoing Philips recalls. SetPoint is trying to treat Crohn's disease with its vagus nerve stimulator. ITC delayed the Apple Watch patent case again.
After an admittedly difficult 2022 for a variety of reasons, Philips Healthcare is ready to tackle 2023 and beyond by reducing business complexities, slimming staff numbers further and crucially implementing a new value creation strategy under recently appointed CEO Roy Jakobs.
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
The integration of smart connected care, broadening of diagnosis and therapy into new settings and improvement of chronic disease outcomes will continue to shape the market for devices and diagnostics companies for years to come. But there is also a maze of short-term macroeconomic issues for medtechs to work through.
- Other Names / Subsidiaries
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.